Teriparatide 10mg

Overview of Teriparatide (PTH 1-34)

RESEARCH USE ONLY: This research product is intended for laboratory laboratory research purposes only. Not for human consumption.

Teriparatide is a synthetic 34-amino-acid peptide. It corresponds to the N-terminal fragment of parathyroid hormone (PTH). It is a parathyroid hormone receptor 1 (PTH1R) agonist and is supplied by PureRawz as a research-grade peptide. It is available for:

• In vitro receptor binding investigation
• Preclinical bone remodelling pathway research, and 
• Osteoblast biology laboratory studies

Important clarification: A pharmaceutical formulation of teriparatide (PTH 1-34, Parathyroid Hormone Fragment 1-34, hPTH(1-34), Parathar, Eli Lilly) is FDA-approved for specific clinical indications. However, the research-grade teriparatide supplied here is a distinct laboratory preparation. It is a 10mg lyophilised peptide vial produced for preclinical and in vitro research use only. It is not a pharmaceutical product, not a clinical preparation, and is not supplied for any human application. It is not a dietary supplement.

Chemical and Molecular Properties

Formulation note for researchers: The acetate salt form (CAS 99294-94-7, MW 4,177.83 g/mol) is also available from some suppliers. The values above reflect the free peptide entry for CAS 52232-67-4. Each PureRawz batch comes with a Certificate of Analysis confirming the specific molecular identity and form of the shipped material.

Mechanisms Investigated in Preclinical Research

PTH1R Receptor Binding and cAMP Signalling Research:

Teriparatide has been investigated in preclinical cell and tissue models as a PTH1R agonist. In isolated receptor preparations and cell culture systems, PTH1R binding by teriparatide has been observed to activate adenylate cyclase, increasing intracellular cAMP levels and activating downstream protein kinase A signalling cascades. This receptor-mediated second messenger pathway is the primary mechanism under investigation in PTH1R pharmacology research.

Osteoblast Activation and Bone Formation Pathway Research:

In rodent preclinical models and isolated osteoblast cell systems, intermittent PTH1R activation by teriparatide has been associated with modulation of osteoblast differentiation, proliferation, and apoptosis pathways. Research in this area has investigated how PTH1R signalling may shift the balance between bone-forming and bone-resorbing cellular activity in experimental model systems. 

RANKL/OPG Pathway Modulation Research:

In animal model studies, teriparatide has been investigated for its potential to modulate RANKL (receptor activator of nuclear factor kappa-B ligand) and osteoprotegerin (OPG) signalling. The interaction between PTH1R activation and the RANKL/OPG axis in bone remodelling model systems remains an active area of preclinical investigation. 

Bone Remodelling Marker Research:

In rat spinal fusion and allograft preclinical models, teriparatide administration has been observed to modulate serum markers of bone formation and resorption, including osteocalcin and CTX-1, in a dose and frequency-dependent manner. This has made it a reference compound in preclinical studies investigating bone remodelling dynamics.

Research Applications

1. PTH1R receptor binding kinetics and structure-activity relationship studies 
2. Osteoblast differentiation and apoptosis pathway investigation in primary cell culture 
3. RANKL/OPG signalling axis research in preclinical bone remodelling model systems
4. Comparative PTH fragment pharmacology studies against full-length PTH(1-84) analogs
5. Bone formation and resorption marker modulation studies (in rodent preclinical models)
6. cAMP second messenger signalling research in PTH1R-transfected cell line systems

Risk & Handling

Teriparatide is a synthetic polypeptide PTH1R agonist under investigation in preclinical bone remodelling research. 

Risk tier: HIGH. Researchers must observe the following precautions at all times.

Handling Precautions: Teriparatide should be handled exclusively in a controlled laboratory environment by trained personnel. Avoid skin and eye contact during reconstitution and handling. Use appropriate PPE at all times.

Exposure Risks: Teriparatide is a PTH1R agonist research peptide that is thought to modulate calcium homeostasis, cAMP signalling, and bone remodelling pathways in preclinical models. No human safety data has been established for the research-grade formulation supplied here.

Storage: Store lyophilised teriparatide at −20°C in a dry, dark environment. Protect from light, heat, and moisture at all times. Avoid repeated freeze-thaw cycles. Use within one month once opened. 

Quality Assurance

• Identity: Confirmed by HPLC retention time and mass spectrometry against CAS 52232-67-4 reference data
• Purity: ≥98% (HPLC verified)
• Batch Traceability: Unique lot numbers for every product
• Certificate of Analysis (COA): Available for every batch — confirms molecular identity, purity, and formulation
• Third-Party Testing: Independent laboratory verification
• Safety Data Sheet (SDS): Available upon request

Why PureRawz

PureRawz supplies research-grade teriparatide with batch-specific Certificates of Analysis. This confirms molecular identity and purity against CAS 52232-67-4 reference data. Given that teriparatide is commercially available in both free peptide and acetate salt forms with different molecular weights, batch-specific identity confirmation is a key parameter for reproducible experimental design. Each lot is characterised by HPLC retention time and mass spectrometry to confirm the specific form of the shipped material.

References

1. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007;40(6):1434–1446. https://purerawlab.com
2. Jilka RL, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. Journal of Clinical Investigation. 1999;104(4):439–446. https://purerawlab.com